Inhibition of Lp-PLA2 Reduces Inflammation and Atherosclerosis in Mice
Author Information
Author(s): Wang Wen-yi, Zhang Jie, Wu Wen-yu, Li Jie, Ma Yan-ling, Chen Wei-hai, Yan Hong, Wang Kai, Xu Wen-wei, Shen Jian-hua, Wang Yi-ping
Primary Institution: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Hypothesis
Does the specific Lp-PLA2 inhibitor darapladib affect atherosclerosis development in ApoE-deficient mice?
Conclusion
Inhibition of Lp-PLA2 by darapladib reduces inflammation and plaque formation in ApoE-deficient mice.
Supporting Evidence
- Serum Lp-PLA2 activity was inhibited by more than 60% after treatment with darapladib.
- Levels of inflammatory markers hs-CRP and IL-6 were significantly reduced in the darapladib group.
- The plaque area in the darapladib group was significantly smaller compared to the control group.
- Macrophage content in atherosclerotic lesions was lower in the darapladib group.
- Collagen content in lesions was higher in the darapladib group, indicating more stable plaques.
- Expression of inflammatory genes MCP-1, VCAM-1, and TNF-α was lower in the darapladib group.
Takeaway
This study shows that a drug called darapladib can help reduce heart disease by lowering inflammation and plaque buildup in mice.
Methodology
ApoE-deficient mice were fed a high-fat diet and treated with darapladib or saline for 6 weeks, followed by analysis of serum and aortic samples.
Limitations
The detailed mechanisms of how darapladib affects atherosclerosis are not fully understood.
Participant Demographics
Male homozygous ApoE-deficient mice (C57/Bl6 genetic background)
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website